Who qualifies for the 340B program?

To qualify for the 340B Drug Pricing Program, a healthcare organization must be recognized as an eligible "covered entity" by the Health Resources and Services Administration (HRSA) and meet strict federal criteria.

Eligible Covered Entities

Participation is limited to specific safety-net hospitals and federal grantees:

• Eligible Hospitals: Must be non-profit, state-operated, or local government-owned, and meet specific utilization thresholds:
  • Disproportionate Share Hospitals (DSH): Must have a Medicare DSH adjustment percentage above 11.75%.
  • Children's and Free-Standing Cancer Hospitals: Must exceed an 11.75% DSH adjustment percentage.
  • Sole Community Hospitals (SCH) and Rural Referral Centers (RRC): Must meet or exceed an 8.00% DSH adjustment percentage.
  • Critical Access Hospitals (CAH): Do not have a minimum DSH percentage requirement.
• Federal Grantees: Automatically qualify if they receive specific federal funding, including:
  • Federally Qualified Health Centers (FQHCs) and Look-Alikes
  • Ryan White HIV/AIDS Program grantees
  • Family planning (Title X), tuberculosis, and black lung clinics

Patient Eligibility Requirements

To receive a 340B-discounted drug, a patient must meet three core criteria set by HRSA Guidelines:

1. Established Care: The individual must be an active patient of the covered entity, which maintains health records documenting their care.
2. Authorized Provider: Care must be provided by a healthcare professional employed by or contracted/referred by the covered entity.
3. Scope of Service: The health service received must match the specific type of care the covered entity is authorized to provide under its grant or designation.

The 340B Drug Pricing Program covers almost all outpatient prescription drugs, biologics, and insulin approved by the U.S. Food and Drug Administration (FDA).

Covered Drug Types

• Brand-name prescription drugs: Covered with statutory discounts.
• Generic prescription drugs: Included at reduced baseline ceiling prices.
• Over-the-counter (OTC) medications: Included if written on a prescription by an authorized provider.
• Specialty and orphan drugs: Included, though specific manufacturer restrictions sometimes apply to orphan drugs for certain hospital types.
• Therapeutic categories: Includes treatments for chronic and acute illnesses, cancer (e.g., Keytruda), diabetes (e.g., Trulicity, Jardiance), HIV/AIDS (e.g., Truvada), and cardiovascular conditions (e.g., Eliquis, Farxiga).

Key Program Rules

• Outpatient use only: Drugs must be used in an outpatient setting; inpatient drugs do not qualify for 340B pricing.
• Manufacturer participation: Any drug maker that sells products through Medicaid must offer these discounted outpatient drugs to eligible safety-net health care organizations (covered entities).

The 340B controversy centers on a major conflict between pharmaceutical companies and hospitals over how a federal drug discount program is used, funded, and managed.

Congress created the 340B Drug Pricing Program in 1992 to help safety-net clinics and hospitals buy outpatient drugs at steep mandatory discounts (ranging from 20% to 50% off) so they could treat low-income and uninsured patients. Over time, the program grew from a small initiative into an $81.4 billion enterprise, leading to intense debate over profits, oversight, and patient care.

Core Issues in the Dispute

• The Profit "Spread": Hospitals can buy drugs cheaply through 340B and bill insurance companies or Medicare at regular, higher rates. Critics argue hospitals use this extra revenue for corporate growth or facilities in wealthy areas rather than charity care. Hospitals counter that these savings keep vital community services afloat.
• Contract Pharmacies: Guidance from 2010 allowed hospitals to partner with an unlimited number of outside "contract pharmacies" to dispense medications. Drugmakers argue this massive expansion—growing to over 30,000 pharmacies—leads to fraud, waste, and duplicate discounts where medications get discounted twice under both 340B and Medicaid.
• Lack of Transparency: Federal law does not require hospitals to report how they spend money saved through 340B, nor does it force them to pass discounts directly on to uninsured patients at the counter.

Recent Developments and Reforms

• Rebate Pilots: The federal government has introduced controversial pilot programs allowing certain drugmakers to replace upfront 340B discounts with back-end post-dispensing rebates.
• Manufacturer Restrictions: Drug companies have tried to limit discounts or cut off supplies to hospitals that do not comply with strict data-sharing and paperwork rules, prompting legal battles from hospital associations.

Yes, the 340B Drug Pricing Program interacts directly with Medicare, primarily through Medicare Part B outpatient drug reimbursements and evolving reporting rules for Part D.

How 340B Interacts with Medicare

• Drug Purchasing Discounts: Drug manufacturers are required to offer discounted prices on outpatient drugs to eligible 340B "covered entities" (which include certain safety-net and Disproportionate Share Hospitals) as a condition of having their drugs covered under Medicaid and Medicare Part B.
• Medicare Part B Reimbursements: Eligible 340B hospitals can purchase outpatient drugs at steep discounts and then bill Medicare and other insurers at standard rates. The Centers for Medicare & Medicaid Services (CMS) regulates how much Medicare pays hospitals for these discounted drugs, with ongoing policy debates and proposed adjustments to reimbursement rates to match acquisition costs.
• Medicare Part D Claims Data: CMS has introduced reporting frameworks and data collection initiatives for 340B-acquired drugs utilized under Medicare Part D to track inflation rebates and adjust program calculations.

No, not just anyone can use a 340B pharmacy to get discounted medication pricing.

To receive 340B-priced drugs, you must be an established patient of a registered 340B-covered entity (such as a qualifying community health center, Federally Qualified Health Center, or eligible hospital) and your prescription must stem directly from care received within that specific provider network.

Key Patient Eligibility Rules

• Active Relationship: You must receive medical care from a healthcare provider at the specific 340B-eligible clinic or hospital.
• Managed Care: The specific prescription must result from an outpatient service or treatment actively managed by that provider.
• Approved Locations: The drugs must be dispensed through the covered entity's in-house pharmacy or an officially approved 340B contract pharmacy linked to your treating provider.

You can verify program guidelines and organizational definitions through the HRSA 340B Eligibility Guide.